Clinical Trial Update: Evaluation of PROCHYMAL® for Treatment-refractory Moderate-to-severe Crohn's Disease [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating PROCHYMAL for treatment-refractory moderate-to-severe Crohn's disease has completed. The sponsor was Mesoblast, and the study status is…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Crohn Disease

Drugs mentioned

• PROCHYMAL (allogeneic mesenchymal stem cells)

Snippet

Sponsor: Mesoblast, Inc. | Conditions: Crohn's Disease | Phase 3 | Status: COMPLETED